Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum [Yahoo! Finance]
Monte Rosa Therapeutics, Inc. (GLUE)
Company Research
Source: Yahoo! Finance
The data showed rapid, sustained reductions in inflammatory markers in subjects with elevated cardiovascular risk and a favorable safety profile. See our latest analysis for Monte Rosa Therapeutics. That clinical update has arrived during a period of sharp price swings, with a 7 day share price return of 58.59% and a 90 day share price return of 141.83%. The 1 year total shareholder return of 325.96% points to strong longer term momentum despite a 1 day share price return of negative 4.07% and recent equity offerings that may have influenced sentiment. If MRT-8102 has you looking more broadly at cardiology and immunology themes, it could be a useful moment to scan other healthcare stocks that might fit your watchlist next. With Monte Rosa now trading near recent highs, an intrinsic discount of roughly 35% and a price target about 24% above the last close, is there still an opening here, or is the market already pricing in future growth? On earnings, Monte Rosa trades on a P/
Show less
Read more
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLUE alerts
High impacting Monte Rosa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GLUE
News
- Monte Rosa Therapeutics (NASDAQ:GLUE) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Monte Rosa Therapeutics announces pricing of $300M stock offering [Seeking Alpha]Seeking Alpha
- Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public OfferingGlobeNewswire
- Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Wells Fargo & Company from $22.00 to $30.00. They now have an "overweight" rating on the stock.MarketBeat
- Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Guggenheim from $16.00 to $34.00. They now have a "buy" rating on the stock.MarketBeat
GLUE
Sec Filings
- 1/9/26 - Form 8-K
- 1/9/26 - Form 424B5
- 1/9/26 - Form SCHEDULE
- GLUE's page on the SEC website